SEC 13F Intelligence

Vantage Consulting Group Inc / ITCIEUR

Vantage Consulting Group Inc’s Intra-Cellular Therapies Inc Position

Does Vantage Consulting Group Inc own Intra-Cellular Therapies Inc (ITCIEUR)? Not currently — the last reported position was 226.7K shares worth $12M in Q4 2021; the fund’s latest 13F (Q4 2025) no longer reports it.

Position Value
$12M
Q4 2021
Shares
226.7K
% of Portfolio
+3.19%
Quarters Held
5
position exited

Position History ITCIEUR

Reported value by quarter
Q4 ’20: $7MQ4 ’20Q1 ’21: $8MQ1 ’21Q2 ’21: $9MQ2 ’21Q3 ’21: $8MQ3 ’21Q4 ’21: $12MQ4 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q4 2021226.7K$12M+3.19%
Q3 2021226.7K$8M+1.81%
Q2 2021226.7K$9M+1.61%
Q1 2021226.7K$8M+1.54%
Q4 2020226.7K$7M+0.59%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Vantage Consulting Group Inc’s full portfolio or all institutional holders of ITCIEUR.